The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Administration for adult patients with R/R DLBCL
On May 21, 2025, China’s National Medical Products Administration (NMPA) granted approval for tafasitamab, a CD19-targeting monoclonal antibody, in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT).1 Tafasitamab plus lenalidomide was previously approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the same indication.1
This approval was based on results from Chinese clinical studies of this combination, which showed similar results to the global L-MIND study (NCT02399085).1 It is the first CD19 antibody approved for the treatment of R/R DLBCL in China.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
.webp&w=3840&q=75)